Other news

u-card-img-1
News
Publication dans Nature Communications

Bloquer les capteurs de spike pour contrer la Covid

David Alsteens (WELBIO – UCLouvain) et son équipe démontrent l’interaction entre les acides sialiques à la surface cellulaire et la protéine spike, et développent des molécules qui permettent de bloquer cette interaction in vitro.

Learn more
u-card-img-1
News

Prix Fondation Médicale Reine Elisabeth 2022

Le Prix Vicomtesse Valine de Spoelberch 2022 de la Fondation Médicale Reine Elisabeth a été attribué à Guido Bommer (WELBIO – UCLouvain) lors d’une cérémonie en présence de S.A.R. la Princesse Astrid.

Learn more
u-card-img-1
News
Résultats de l'appel 2021

23 nouveaux programmes WELBIO

Les résultats de l'appel 2021 sont connus: plus de 13 millions € pour 23 nouveaux programmes WELBIO !

Learn more
u-card-img-1
News
Prix Baillet Latour 2022

Prix Baillet Latour Biomedical à Thomas Marichal

Thomas Marichal (WELBIO - ULiège) est le lauréat du prestigieux Prix Baillet Latour Biomedical qui vise à soutenir pendant 5 ans la carrière de jeunes chercheurs/chercheuses prometteurs dans le domaine des sciences biomédicales.

Learn more
u-card-img-1
News

Rapport annuel 2021

Découvrez nos chercheurs, leurs avancées scientifiques et comment certaines découvertes ont été traduites en applications pour la santé humaine.

Learn more
u-card-img-1
News
Publication in Science Translational Medicine

Genetic cause identified for a severe form of lymphedema

The team of Miikka Vikkula (WELBIO - UCLouvain) and colleagues have discovered a genetic cause for CCLA, a serious and rare disease affecting the central lymphatic vessel system.

Learn more
u-card-img-1
News
Publication in Science

An innovative approach to treating brain diseases

Benoît Vanholleke (WELBIO-ULB) and his team found how modulating Gpr124/ restores the permeability of cerebral blood vessels in models of brain pathologies.  

Learn more
u-card-img-1
News
Publication in PNAS

A link between sugar metabolism and Parkinson’s disease

Guido Bommer (WELBIO-UCLouvain) and his team identify a new role for PARK7  an enzyme that is inactive in some Parkinson's disease patients.

Learn more
u-card-img-1
News
Publication in NANOLetters

Nanobiophysical approach offers new perspectives for oncolytic cancer therapy

David Alsteens (WELBIO - UCLouvain) and his team demonstrate the role of α-sialylated glycans in enhancing oncolytic therapy in breast cancer using atomic force microscopy.

Learn more
u-card-img-1
News
European Association for Cancer Research (EACR) Prize

EACR’s Mike Gold Medal Award 2022 to Cédric Blanpain

Cédric Blanpain (WELBIO - ULB) is the 2022 winner of the EACR’s Mike Price Gold Medal, which rewards a senior researcher who has made an outstanding contribution to the progress of cancer research in Europe.

Learn more
u-card-img-1
News
Publication in Oncogene

A dual role for COP1 in breast cancer

Alain Chariot (WELBIO – ULiège) and his team demonstrated that COP1 can act as an oncogenic E3 ligase by promoting ERa signaling but also as a tumor suppressor candidate by preventing epithelial-mesenchymal transition.

Learn more
u-card-img-1
News
Spin-off creation

Santero Therapeutics: Towards a new generation of antibiotics

From fundamental research on bacterial metabolism in Abel Garcia-Pino's laboratory (WELBIO - ULB) to the development of a new generation of antibiotics.

Learn more

Share this page